Baroreflex Activation Therapy in Congestive Heart Failure: Novel Findings and Future Insights

Guido Grassi, Gianmaria Brambilla, Daniela Prata Pizzalla, Gino Luciano Seravalle

Research output: Contribution to journalReview article

Abstract

Congestive heart failure is characterized by hemodynamic and non-hemodynamic abnormalities, the latter including an activation of the sympathetic influences to the heart and peripheral circulation coupled with an impairment of baroreceptor control of autonomic function. Evidence has been provided that both these alterations are hallmark features of the disease with a specific relevance for the disease progression as well as for the development of life-threatening cardiac arrhythmias. In addition, a number of studies have documented in heart failure the adverse prognostic role of the sympathetic and baroreflex alterations, which both are regarded as major independent determinants of cardiovascular morbidity and mortality. This represents the pathophysiological and clinical background for the use of carotid baroreceptor activation therapy in the treatment of congestive heart failure. Promising data collected in experimental animal models of heart failure have supported the recent performance of pilot small-scale clinical studies, aimed at providing initial information in this area. The results of these studies demonstrated the clinical safety and efficacy of the intervention which has been tested in large-scale clinical studies. The present paper will critically review the background and main results of the published studies designed at defining the clinical impact of baroreflex activation therapy in congestive heart failure patients. Emphasis will be given to the strengths and limitations of such studies, which represent the background for the ongoing clinical trials testing the long-term effects of the device in heart failure patients.

Original languageEnglish
Article number60
JournalCurrent Hypertension Reports
Volume18
Issue number8
DOIs
Publication statusPublished - Aug 1 2016

Fingerprint

Baroreflex
Heart Failure
Pressoreceptors
Therapeutics
Disease Progression
Cardiac Arrhythmias
Animal Models
Hemodynamics
Clinical Trials
Morbidity
Safety
Equipment and Supplies
Mortality

Keywords

  • Arterial baroreceptors
  • Baroreflex activation therapy
  • Congestive heart failure
  • Mortality
  • Sympathetic nervous system

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Baroreflex Activation Therapy in Congestive Heart Failure : Novel Findings and Future Insights. / Grassi, Guido; Brambilla, Gianmaria; Pizzalla, Daniela Prata; Seravalle, Gino Luciano.

In: Current Hypertension Reports, Vol. 18, No. 8, 60, 01.08.2016.

Research output: Contribution to journalReview article

@article{76fce9067b054f288162dca11e448c3a,
title = "Baroreflex Activation Therapy in Congestive Heart Failure: Novel Findings and Future Insights",
abstract = "Congestive heart failure is characterized by hemodynamic and non-hemodynamic abnormalities, the latter including an activation of the sympathetic influences to the heart and peripheral circulation coupled with an impairment of baroreceptor control of autonomic function. Evidence has been provided that both these alterations are hallmark features of the disease with a specific relevance for the disease progression as well as for the development of life-threatening cardiac arrhythmias. In addition, a number of studies have documented in heart failure the adverse prognostic role of the sympathetic and baroreflex alterations, which both are regarded as major independent determinants of cardiovascular morbidity and mortality. This represents the pathophysiological and clinical background for the use of carotid baroreceptor activation therapy in the treatment of congestive heart failure. Promising data collected in experimental animal models of heart failure have supported the recent performance of pilot small-scale clinical studies, aimed at providing initial information in this area. The results of these studies demonstrated the clinical safety and efficacy of the intervention which has been tested in large-scale clinical studies. The present paper will critically review the background and main results of the published studies designed at defining the clinical impact of baroreflex activation therapy in congestive heart failure patients. Emphasis will be given to the strengths and limitations of such studies, which represent the background for the ongoing clinical trials testing the long-term effects of the device in heart failure patients.",
keywords = "Arterial baroreceptors, Baroreflex activation therapy, Congestive heart failure, Mortality, Sympathetic nervous system",
author = "Guido Grassi and Gianmaria Brambilla and Pizzalla, {Daniela Prata} and Seravalle, {Gino Luciano}",
year = "2016",
month = "8",
day = "1",
doi = "10.1007/s11906-016-0667-0",
language = "English",
volume = "18",
journal = "Current Hypertension Reports",
issn = "1522-6417",
publisher = "Current Medicine Group",
number = "8",

}

TY - JOUR

T1 - Baroreflex Activation Therapy in Congestive Heart Failure

T2 - Novel Findings and Future Insights

AU - Grassi, Guido

AU - Brambilla, Gianmaria

AU - Pizzalla, Daniela Prata

AU - Seravalle, Gino Luciano

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Congestive heart failure is characterized by hemodynamic and non-hemodynamic abnormalities, the latter including an activation of the sympathetic influences to the heart and peripheral circulation coupled with an impairment of baroreceptor control of autonomic function. Evidence has been provided that both these alterations are hallmark features of the disease with a specific relevance for the disease progression as well as for the development of life-threatening cardiac arrhythmias. In addition, a number of studies have documented in heart failure the adverse prognostic role of the sympathetic and baroreflex alterations, which both are regarded as major independent determinants of cardiovascular morbidity and mortality. This represents the pathophysiological and clinical background for the use of carotid baroreceptor activation therapy in the treatment of congestive heart failure. Promising data collected in experimental animal models of heart failure have supported the recent performance of pilot small-scale clinical studies, aimed at providing initial information in this area. The results of these studies demonstrated the clinical safety and efficacy of the intervention which has been tested in large-scale clinical studies. The present paper will critically review the background and main results of the published studies designed at defining the clinical impact of baroreflex activation therapy in congestive heart failure patients. Emphasis will be given to the strengths and limitations of such studies, which represent the background for the ongoing clinical trials testing the long-term effects of the device in heart failure patients.

AB - Congestive heart failure is characterized by hemodynamic and non-hemodynamic abnormalities, the latter including an activation of the sympathetic influences to the heart and peripheral circulation coupled with an impairment of baroreceptor control of autonomic function. Evidence has been provided that both these alterations are hallmark features of the disease with a specific relevance for the disease progression as well as for the development of life-threatening cardiac arrhythmias. In addition, a number of studies have documented in heart failure the adverse prognostic role of the sympathetic and baroreflex alterations, which both are regarded as major independent determinants of cardiovascular morbidity and mortality. This represents the pathophysiological and clinical background for the use of carotid baroreceptor activation therapy in the treatment of congestive heart failure. Promising data collected in experimental animal models of heart failure have supported the recent performance of pilot small-scale clinical studies, aimed at providing initial information in this area. The results of these studies demonstrated the clinical safety and efficacy of the intervention which has been tested in large-scale clinical studies. The present paper will critically review the background and main results of the published studies designed at defining the clinical impact of baroreflex activation therapy in congestive heart failure patients. Emphasis will be given to the strengths and limitations of such studies, which represent the background for the ongoing clinical trials testing the long-term effects of the device in heart failure patients.

KW - Arterial baroreceptors

KW - Baroreflex activation therapy

KW - Congestive heart failure

KW - Mortality

KW - Sympathetic nervous system

UR - http://www.scopus.com/inward/record.url?scp=84976502130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976502130&partnerID=8YFLogxK

U2 - 10.1007/s11906-016-0667-0

DO - 10.1007/s11906-016-0667-0

M3 - Review article

VL - 18

JO - Current Hypertension Reports

JF - Current Hypertension Reports

SN - 1522-6417

IS - 8

M1 - 60

ER -